JP2025510074A5 - - Google Patents
Info
- Publication number
- JP2025510074A5 JP2025510074A5 JP2024556319A JP2024556319A JP2025510074A5 JP 2025510074 A5 JP2025510074 A5 JP 2025510074A5 JP 2024556319 A JP2024556319 A JP 2024556319A JP 2024556319 A JP2024556319 A JP 2024556319A JP 2025510074 A5 JP2025510074 A5 JP 2025510074A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- tautomer
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204142.0A GB202204142D0 (en) | 2022-03-24 | 2022-03-24 | Novel compounds |
| GB2204142.0 | 2022-03-24 | ||
| GBGB2213816.8A GB202213816D0 (en) | 2022-09-22 | 2022-09-22 | Novel compounds |
| GB2213816.8 | 2022-09-22 | ||
| GBGB2301448.3A GB202301448D0 (en) | 2023-02-01 | 2023-02-01 | Novel compounds |
| GB2301448.3 | 2023-02-01 | ||
| GB202301757 | 2023-02-08 | ||
| GB2301757.7 | 2023-02-08 | ||
| PCT/EP2023/057338 WO2023180388A1 (en) | 2022-03-24 | 2023-03-22 | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510074A JP2025510074A (ja) | 2025-04-14 |
| JP2025510074A5 true JP2025510074A5 (https=) | 2026-03-30 |
Family
ID=85937360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556319A Pending JP2025510074A (ja) | 2022-03-24 | 2023-03-22 | Ｐｒｏｔａｃにおけるデグロンとしての２，４－ジオキソテトラヒドロピリミジニル誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250205344A1 (https=) |
| EP (1) | EP4499628A1 (https=) |
| JP (1) | JP2025510074A (https=) |
| CN (1) | CN119301111A (https=) |
| CA (1) | CA3246569A1 (https=) |
| WO (1) | WO2023180388A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4647431A1 (en) * | 2023-01-04 | 2025-11-12 | Gan & lee Pharm Co., Ltd. | Compound and method for targeted degradation of androgen receptor |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| WO2025011623A1 (zh) * | 2023-07-12 | 2025-01-16 | 上海壹迪生物技术有限公司 | 氰基喹啉类靶向蛋白降解分子、其制备方法和应用 |
| TW202530192A (zh) | 2023-09-22 | 2025-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 新穎化合物 |
| TW202532055A (zh) * | 2023-11-22 | 2025-08-16 | 大陸商廣東東陽光藥業股份有限公司 | 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途 |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025261436A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| EP3917916A4 (en) | 2019-01-30 | 2022-12-14 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN114269331A (zh) | 2019-03-28 | 2022-04-01 | 埃萨制药股份有限公司 | 雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法 |
| WO2020211822A1 (zh) | 2019-04-18 | 2020-10-22 | 成都海创药业有限公司 | 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途 |
| US12331061B2 (en) | 2019-04-18 | 2025-06-17 | Accutar Biotechnology Inc. | Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| CA3195695A1 (en) | 2020-09-30 | 2022-04-07 | Astrazeneca Ab | Compounds and their use in treating cancer |
-
2023
- 2023-03-22 US US18/849,815 patent/US20250205344A1/en active Pending
- 2023-03-22 CN CN202380029742.4A patent/CN119301111A/zh active Pending
- 2023-03-22 JP JP2024556319A patent/JP2025510074A/ja active Pending
- 2023-03-22 WO PCT/EP2023/057338 patent/WO2023180388A1/en not_active Ceased
- 2023-03-22 EP EP23715429.9A patent/EP4499628A1/en active Pending
- 2023-03-22 CA CA3246569A patent/CA3246569A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510074A5 (https=) | ||
| JP2007511504A5 (https=) | ||
| ES2281565T3 (es) | Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida. | |
| JP6506836B2 (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン | |
| JP2011527334A5 (https=) | ||
| JP2025160318A5 (https=) | ||
| CN105646389B (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 | |
| JP2013544261A5 (https=) | ||
| JP2024509818A5 (https=) | ||
| JP2022533069A5 (https=) | ||
| JP2010500293A5 (https=) | ||
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| JP2009530424A5 (https=) | ||
| JP2014516360A5 (https=) | ||
| CA2579915A1 (en) | Indole derivatives and their use as inhibitors of p53-mdm2 interaction | |
| JP2007517035A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| JP2009533410A5 (https=) | ||
| JP2009534398A5 (https=) | ||
| CA2558506A1 (en) | Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles | |
| JP2006507355A5 (https=) | ||
| JP2005511545A5 (https=) | ||
| JP2022516427A5 (https=) | ||
| JP2009525312A5 (https=) | ||
| JP2007515419A5 (https=) |